{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:45:54Z","timestamp":1794728754442,"version":"4.9.1"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have become an important part of the treatment of multiple cancers, especially for advanced melanoma and non-small cell lung cancer. Some tumors are capable of escaping immunosurveillance by stimulating checkpoints on T-cells. ICIs prevent activation of these checkpoints and thereby stimulate the immune system and indirectly the anti-tumor response. However, the use of ICIs is associated with various adverse events. Ocular side effects are rare but may have a major impact on the quality of life of the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search of the medical databases Web of Science, Embase and PubMed was performed. Articles that provided a comprehensive description of a case report containing 1) cancer patient(s) treated with (a combination of) immune checkpoint inhibitors, and 2) assessed occurrence of ocular adverse events, were included. A total of 290 case reports were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Melanoma (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009179; 61.7%) and lung cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200956; 19.3%) were the most frequent reported malignancies. The primary used ICIs were nivolumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009123; 42.5%) and ipilimumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009116; 40.0%). Uveitis was most the common adverse event (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009134; 46.2%) and mainly related to melanoma. Neuro-ophthalmic disorders, including myasthenia gravis and cranial nerve disorders, were the second most common adverse events (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200971; 24.5%), mainly related to lung cancer. Adverse events affecting the orbit and the cornea were reported in 33 (11.4%) and 30 cases (10.3%) respectively. Adverse events concerning the retina were reported in 26 cases (9.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The aim of this paper is to provide an overview of all reported ocular adverse events related to the use of ICIs. The insights retrieved from this review might contribute to a better understanding of the underlying mechanisms of these ocular adverse events. Particularly, the difference between actual immune-related adverse events and paraneoplastic syndromes might be relevant. These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-022-00321-2","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T09:03:59Z","timestamp":1677056639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Ocular adverse events associated with immune checkpoint inhibitors, a scoping review"],"prefix":"10.1186","volume":"13","author":[{"given":"A.","family":"Martens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P.","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Madoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Casteels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"8","key":"321_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","volume":"181","author":"S Cousin","year":"2018","unstructured":"Cousin S, Seneschal J, Italiano A (2018) Toxicity profiles of immunotherapy. Pharmacol Ther 181:91\u2013100","journal-title":"Pharmacol Ther"},{"issue":"6","key":"321_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38(6):1063\u20131078","journal-title":"Retina"},{"issue":"Suppl 7","key":"321_CR4","doi-asserted-by":"publisher","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","volume":"58","author":"L Spiers","year":"2019","unstructured":"Spiers L, Coupe N, Payne M (2019) Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford) 58(Suppl 7):vii7\u2013vii16","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"321_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","volume":"28","author":"J Antoun","year":"2016","unstructured":"Antoun J, Titah C, Cochereau I (2016) Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol 28(4):288\u2013294","journal-title":"Curr Opin Oncol"},{"key":"321_CR6","doi-asserted-by":"crossref","unstructured":"Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, Habot-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocul Immunol Inflamm. 2020:1\u20137.","DOI":"10.1080\/09273948.2020.1773867"},{"issue":"7","key":"321_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS ONE 11(7):e0160221","journal-title":"PLoS ONE"},{"key":"321_CR8","doi-asserted-by":"crossref","unstructured":"Sun Mm M.D PD, Levinson RMD, Filipowicz ADO, Anesi SMD, Kaplan HMD, Wang W M.D PD, et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm. 2020;28(2):217\u201327.","DOI":"10.1080\/09273948.2019.1577978"},{"issue":"7","key":"321_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","volume":"126","author":"JM Kim","year":"2019","unstructured":"Kim JM, Materin MA, Sznol M, Kluger HM, Weiss S, Chow J et al (2019) Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology 126(7):1058\u20131062","journal-title":"Ophthalmology"},{"issue":"6","key":"321_CR10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","volume":"28","author":"CW Noble","year":"2020","unstructured":"Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM et al (2020) Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 28(6):854\u2013859","journal-title":"Ocul Immunol Inflamm"},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","volume":"202","author":"K Bitton","year":"2019","unstructured":"Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A et al (2019) Prevalence and clinical patterns of ocular complications associated with Anti-PD-1\/PD-L1 anticancer immunotherapy. Am J Ophthalmol 202:109\u2013117","journal-title":"Am J Ophthalmol"},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"175883592199298","DOI":"10.1177\/1758835921992989","volume":"13","author":"O Shahzad","year":"2021","unstructured":"Shahzad O, Thompson N, Clare G, Welsh S, Damato E, Corrie P (2021) Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. Ther Adv Med Oncol 13:1758835921992989","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"321_CR13","first-page":"8","volume":"3","author":"DM Baughman","year":"2017","unstructured":"Baughman DM, Lee CS, Snydsman BE, Jung HC (2017) Bilateral Uveitis and Keratitis Following Nivolumab treatment for Metastatic Melanoma. Med Case Rep (Wilmington) 3(2):8","journal-title":"Med Case Rep (Wilmington)"},{"issue":"2","key":"321_CR14","first-page":"140","volume":"24","author":"E Papavasileiou","year":"2016","unstructured":"Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM (2016) Ipilimumab-induced ocular and orbital inflammation\u2013a case series and review of the literature. Ocul Immunol Inflamm 24(2):140\u2013146","journal-title":"Ocul Immunol Inflamm"},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajoc.2018.02.005","volume":"10","author":"JA Gonzales","year":"2018","unstructured":"Gonzales JA, Shantha J, Acharya NR (2018) Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis. Am J Ophthalmol Case Rep 10:117\u2013118","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"321_CR16","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.5301\/ejo.5000724","volume":"26","author":"K Abu Samra","year":"2016","unstructured":"Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD (2016) A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 26(3):e46\u2013e48","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"321_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/09273948.2019.1678652","volume":"28","author":"TR Ahmad","year":"2020","unstructured":"Ahmad TR, Doan T, Gonzales JA, Acharya NR, Tsui E (2020) Clinical course of preexisting uveitis during treatment of lung cancer with durvalumab. Ocul Immunol Inflamm 28(4):566\u2013570","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"321_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","volume":"44","author":"T Arai","year":"2017","unstructured":"Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R (2017) Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 44(8):975\u2013976","journal-title":"J Dermatol"},{"issue":"1","key":"321_CR19","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jcjo.2015.09.008","volume":"51","author":"A Basilious","year":"2016","unstructured":"Basilious A, Lloyd JC (2016) Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol 51(1):e4-6","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"321_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/tjo.tjo_88_17","volume":"8","author":"CJ Chang","year":"2018","unstructured":"Chang CJ, Chen SJ, Hwang DK, Liu CJ (2018) Bilateral anterior uveitis after immunotherapy for malignant melanoma. Taiwan J Ophthalmol 8(3):173\u2013175","journal-title":"Taiwan J Ophthalmol"},{"key":"321_CR21","doi-asserted-by":"crossref","unstructured":"Deitch-Harel IM, Raskin EM, Habot-Wilner ZM, Friling RM, Amer RM, Kramer MM. Uveitis Induced by Biological Agents Used in Cancer Therapy. Ocul Immunol Inflamm. 2020:1\u20135.","DOI":"10.1080\/09273948.2020.1760310"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","volume":"144","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Urner-Bloch U, Eggenschwiler C, Mitsakakis N, Mangana J, Dummer R et al (2021) The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer 144:215\u2013223","journal-title":"Eur J Cancer"},{"issue":"10","key":"321_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41433-019-0473-4","volume":"33","author":"MJ Dolaghan","year":"2019","unstructured":"Dolaghan MJ, Oladipo B, Cooke CA, McAvoy CE (2019) Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland. Eye (Lond) 33(10):1670\u20131672","journal-title":"Eye (Lond)"},{"issue":"1","key":"321_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","volume":"6","author":"L Hahn","year":"2016","unstructured":"Hahn L, Pepple KL (2016) Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect 6(1):14","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"11","key":"321_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jiac.2017.04.007","volume":"23","author":"H Kanno","year":"2017","unstructured":"Kanno H, Ishida K, Yamada W, Nishida T, Takahashi N, Mochizuki K et al (2017) Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J Infect Chemother 23(11):774\u2013777","journal-title":"J Infect Chemother"},{"issue":"2","key":"321_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/09273948.2016.1215473","volume":"26","author":"J Karlin","year":"2018","unstructured":"Karlin J, Gentzler R, Golen J (2018) Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 26(2):283\u2013285","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"321_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000448730","volume":"7","author":"H Kiratli","year":"2016","unstructured":"Kiratli H, Mocan MC, Irkec M (2016) In vivo confocal microscopy in differentiating ipilimumab-induced anterior uveitis from metastatic uveal melanoma. Case Rep Ophthalmol 7(3):126\u2013131","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"321_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1101204","volume":"5","author":"SS Kwek","year":"2016","unstructured":"Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L et al (2016) GM-CSF and ipilimumab therapy in metastatic melanoma: clinical outcomes and immunologic responses. Oncoimmunology 5(4):e1101204","journal-title":"Oncoimmunology"},{"issue":"3","key":"321_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000509629","volume":"11","author":"JC Lee","year":"2020","unstructured":"Lee JC, Al-Humimat G, Kooner KS (2020) Acute bilateral uveitis, hypotony, and cataracts associated with ipilimumab and nivolumab therapy: optical coherence tomography angiography findings. Case Rep Ophthalmol 11(3):606\u2013611","journal-title":"Case Rep Ophthalmol"},{"issue":"1","key":"321_CR30","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.jcjo.2014.10.010","volume":"50","author":"E Miserocchi","year":"2015","unstructured":"Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50(1):e2-4","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"321_CR31","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","volume":"12","author":"NN Nallapaneni","year":"2014","unstructured":"Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK (2014) Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw 12(8):1077\u20131081","journal-title":"J Natl Compr Canc Netw"},{"key":"321_CR32","unstructured":"Parikh RA, Chaon BC, Berkenstock MK. Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series. Ocul Immunol Inflamm. 2020:1\u20136."},{"issue":"7","key":"321_CR33","first-page":"1183","volume":"10","author":"DR Richardson","year":"2017","unstructured":"Richardson DR, Ellis B, Mehmi I, Leys M (2017) Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol 10(7):1183\u20131186","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"321_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12886-017-0611-3","volume":"17","author":"C Theillac","year":"2017","unstructured":"Theillac C, Straub M, Breton AL, Thomas L, Dalle S (2017) Bilateral uveitis and macular edema induced by Nivolumab: a case report. BMC Ophthalmol 17(1):227","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"321_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaophthalmol.2018.0920","volume":"136","author":"M Thomas","year":"2018","unstructured":"Thomas M, Armenti ST, Ayres MB, Demirci H (2018) Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol 136(5):553\u2013556","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"321_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jamaophthalmol.2017.4872","volume":"135","author":"E Tsui","year":"2017","unstructured":"Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS (2017) Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment. JAMA Ophthalmol 135(12):1455\u20131457","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"321_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1080\/09273948.2019.1582785","volume":"28","author":"M Yoshida","year":"2020","unstructured":"Yoshida M, Kunikata H, Nakazawa T (2020) Intraocular concentrations of cytokines and chemokines in a unique case of nivolumab-induced uveitis. Ocul Immunol Inflamm 28(6):850\u2013853","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"321_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/pcmr.12607","volume":"30","author":"PY Chan","year":"2017","unstructured":"Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW (2017) A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res 30(6):558\u2013562","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"321_CR39","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/09273948.2019.1685111","volume":"29","author":"M Mozo Cuadrado","year":"2021","unstructured":"Mozo Cuadrado M, Tabuenca Del Barrio L, Compains SE (2021) Bilateral drug-induced uveitis and epiretinal membrane during the treatment of a metastatic cutaneous melanoma. Ocul Immunol Inflamm 29(3):543\u2013545","journal-title":"Ocul Immunol Inflamm"},{"key":"321_CR40","first-page":"9","volume":"8","author":"J Sun","year":"2008","unstructured":"Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P (2008) Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9","journal-title":"Cancer Immun"},{"key":"321_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.549168","volume":"10","author":"L Peng","year":"2020","unstructured":"Peng L, Mao QQ, Jiang B, Zhang J, Zhao YL, Teng XD et al (2020) Bilateral posterior uveitis and retinal detachment during immunotherapy: a case report and literature review. Front Oncol 10:549168","journal-title":"Front Oncol"},{"issue":"7","key":"321_CR42","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/ceo.13197","volume":"46","author":"AX Tan","year":"2018","unstructured":"Tan AX, Ang A, Campbell WG, Fabinyi DC (2018) Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma. Clin Exp Ophthalmol 46(7):819\u2013821","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"321_CR43","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1177\/1078155219841683","volume":"25","author":"M Telfah","year":"2019","unstructured":"Telfah M, Whittaker TJ, CD G (2019) Vision loss with pembrolizumab treatment: a report of two cases. J Oncol Pharm Pract 25(6):1540\u20136","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"321_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","volume":"256","author":"CD Conrady","year":"2018","unstructured":"Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A (2018) Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 256(1):187\u2013191","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"321_CR45","doi-asserted-by":"crossref","unstructured":"de Vries EW, Schauwvlieghe AS, Haanen JB, de Hoog J. Bilateral Serous Retinal Detachment and Uveitis Associated with Pembrolizumab Treatment in Metastatic Melanoma. Retin Cases Brief Rep. 2020.","DOI":"10.1097\/ICB.0000000000000999"},{"key":"321_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100691","volume":"18","author":"CR Dermarkarian","year":"2020","unstructured":"Dermarkarian CR, Patel NA, Villegas VM, Harbour JW (2020) Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. Am J Ophthalmol Case Rep 18:100691","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"321_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CJI.0000000000000143","volume":"39","author":"S Diem","year":"2016","unstructured":"Diem S, Keller F, Ruesch R, Maillard SA, Speiser DE, Dummer R et al (2016) Pembrolizumab-triggered Uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother 39(9):379\u2013382","journal-title":"J Immunother"},{"issue":"4","key":"321_CR48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0042-102668","volume":"233","author":"FC Fierz","year":"2016","unstructured":"Fierz FC, Meier F, Chaloupka K, Boni C (2016) Intraocular inflammation associated with new therapies for cutaneous melanoma - case series and review. Klin Monbl Augenheilkd 233(4):540\u2013544","journal-title":"Klin Monbl Augenheilkd"},{"issue":"11","key":"321_CR49","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1002\/phar.1839","volume":"36","author":"KS Hanna","year":"2016","unstructured":"Hanna KS (2016) A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy 36(11):e183\u2013e188","journal-title":"Pharmacotherapy"},{"key":"321_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101072","volume":"22","author":"KW Kim","year":"2021","unstructured":"Kim KW, Kusuhara S, Tachihara M, Mimura C, Matsumiya W, Nakamura M (2021) A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. Am J Ophthalmol Case Rep 22:101072","journal-title":"Am J Ophthalmol Case Rep"},{"key":"321_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ajoc.2016.12.014","volume":"5","author":"QK Lise","year":"2017","unstructured":"Lise QK, Audrey AG (2017) Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab. Am J Ophthalmol Case Rep 5:92\u201393","journal-title":"Am J Ophthalmol Case Rep"},{"key":"321_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ajoc.2018.01.030","volume":"10","author":"SR Patel","year":"2018","unstructured":"Patel SR, Moysidis SN, Koulisis N, Storey PP, Kashani AH, Rao NA et al (2018) Is it melanoma-associated retinopathy or drug toxicity? bilateral cystoid macular edema posing a diagnostic and therapeutic dilemma. Am J Ophthalmol Case Rep 10:77\u201380","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"321_CR53","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1080\/09273948.2018.1459733","volume":"27","author":"G Reid","year":"2019","unstructured":"Reid G, Lorigan P, Heimann H, Hovan M (2019) Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm 27(6):1012\u20131015","journal-title":"Ocul Immunol Inflamm"},{"key":"321_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajoc.2016.04.004","volume":"2","author":"SC Taylor","year":"2016","unstructured":"Taylor SC, Hrisomalos F, Linette GP, Rao PK (2016) A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy. Am J Ophthalmol Case Rep 2:23\u201325","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"321_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bjophthalmol-2019-314403","volume":"104","author":"AG Venkat","year":"2020","unstructured":"Venkat AG, Arepalli S, Sharma S, Karthik N, Lowder C, Ehlers JP et al (2020) Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. Br J Ophthalmol 104(5):703\u2013711","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"321_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00262-018-2260-7","volume":"68","author":"W Wang","year":"2019","unstructured":"Wang W, Lam WC, Chen L (2019) Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 68(1):85\u201395","journal-title":"Cancer Immunol Immunother"},{"key":"321_CR57","doi-asserted-by":"crossref","unstructured":"J LH, L MB, El Rahi C, A CS, Bernicker EH. Panuveitis in patient on ipilimumab\/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant. J Oncol Pharm Pract. 2021;27(5):1261\u20134.","DOI":"10.1177\/1078155220969792"},{"issue":"2","key":"321_CR58","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/art.39406","volume":"68","author":"G de Velasco","year":"2016","unstructured":"de Velasco G, Bermas B, Choueiri TK (2016) Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 68(2):556\u2013557","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"321_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589\u2013593","journal-title":"Neuro Oncol"},{"issue":"4","key":"321_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.730","volume":"9","author":"C Mimura","year":"2021","unstructured":"Mimura C, Tachihara M, Kusuhara S, Fukuoka H, Nishimura Y (2021) Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis. Respirol Case Rep 9(4):e00730","journal-title":"Respirol Case Rep"},{"issue":"4","key":"321_CR61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/15569527.2013.781618","volume":"32","author":"BS Modjtahedi","year":"2013","unstructured":"Modjtahedi BS, Maibach H, Park S (2013) Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 32(4):341\u2013343","journal-title":"Cutan Ocul Toxicol"},{"issue":"12","key":"321_CR62","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.4103\/ijo.IJO_1161_19","volume":"67","author":"C Navarro-Perea","year":"2019","unstructured":"Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E (2019) Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol 67(12):2075\u20132077","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"321_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout M, Petre A, Amini-Adle M, Bezza W, Seve P, Kodjikian L et al (2017) Vogt-Koyanagi-harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother 40(2):77\u201382","journal-title":"J Immunother"},{"issue":"6","key":"321_CR64","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3928\/23258160-20150610-10","volume":"46","author":"J Crews","year":"2015","unstructured":"Crews J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD (2015) Ipilimumab-associated retinopathy. Ophthalmic Surg Lasers Imaging Retina 46(6):658\u2013660","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"321_CR65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","volume":"38","author":"JN Crosson","year":"2015","unstructured":"Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S (2015) Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 38(2):80\u201384","journal-title":"J Immunother"},{"issue":"3","key":"321_CR66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10633-020-09800-0","volume":"142","author":"H Enomoto","year":"2021","unstructured":"Enomoto H, Kato K, Sugawara A, Itabashi M, Kondo M (2021) Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment. Doc Ophthalmol 142(3):353\u2013360","journal-title":"Doc Ophthalmol"},{"issue":"6","key":"321_CR67","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol 45(6):735\u2013737","journal-title":"J Dermatol"},{"issue":"7","key":"321_CR68","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/imt-2019-0206","volume":"12","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12(7):439\u2013444","journal-title":"Immunotherapy"},{"issue":"1","key":"321_CR69","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","volume":"20","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Kawagoe T, Hotta K (2020) Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 20(1):252","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"321_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.545","volume":"8","author":"Y Kurono","year":"2020","unstructured":"Kurono Y, Takeda T, Kunimatsu Y, Tani N, Hashimoto I, Hirose K (2020) Vogt-Koyanagi-Harada disease during chemoimmunotherapy for non-small cell lung cancer. Respirol Case Rep 8(3):e00545","journal-title":"Respirol Case Rep"},{"issue":"6","key":"321_CR71","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/09273948.2019.1604975","volume":"28","author":"J Lee","year":"2020","unstructured":"Lee J, Shin JY, Lee JS, Lee SC, Hong MH, Lee CS (2020) Recurrent sympathetic ophthalmia with annular choroidal detachment after pembrolizumab treatment: a case report. Ocul Immunol Inflamm 28(6):864\u2013867","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"321_CR72","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O (2017) Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5(5):694\u2013700","journal-title":"Clin Case Rep"},{"issue":"1","key":"321_CR73","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12885-018-4470-y","volume":"18","author":"MA McDonald","year":"2018","unstructured":"McDonald MA, Sanghvi P, Bykowski J, Daniels GA (2018) Unmasking of intracranial metastatic melanoma during ipilimumab\/nivolumab therapy: case report and literature review. BMC Cancer 18(1):549","journal-title":"BMC Cancer"},{"issue":"5","key":"321_CR74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00347-019-00963-z","volume":"117","author":"N Mihailovic","year":"2020","unstructured":"Mihailovic N, Dyballa J, Herz S, Fluck M, Alnawaiseh M, Mert\u00e9 RL et al (2020) Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma. Ophthalmologe 117(5):467\u2013471","journal-title":"Ophthalmologe"},{"issue":"1","key":"321_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M (2019) Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 10(1):67\u201374","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"321_CR76","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/ICB.0000000000000785","volume":"15","author":"BE O'Bryhim","year":"2021","unstructured":"O\u2019Bryhim BE, Sychev Y, Rao PK (2021) Bilateral choroidal detachments secondary to ipilimumab and pembrolizumab use. Retin Cases Brief Rep 15(3):230\u2013233","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"321_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-019-0533-0","volume":"7","author":"S Rapisuwon","year":"2019","unstructured":"Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P et al (2019) Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer 7(1):61","journal-title":"J Immunother Cancer"},{"issue":"10","key":"321_CR78","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.jtho.2018.04.026","volume":"13","author":"T Tamura","year":"2018","unstructured":"Tamura T, Akimoto E, Matsumoto C, Mori S, Nishi T, Kudo K et al (2018) Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer. J Thorac Oncol 13(10):1606\u20131607","journal-title":"J Thorac Oncol"},{"issue":"11","key":"321_CR79","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3928\/23258160-20171030-09","volume":"48","author":"MT Witmer","year":"2017","unstructured":"Witmer MT (2017) Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone. Ophthalmic Surg Lasers Imaging Retina 48(11):928\u2013931","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"321_CR80","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","volume":"6","author":"RK Wong","year":"2012","unstructured":"Wong RK, Lee JK, Huang JJ (2012) Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 6(4):423\u2013426","journal-title":"Retin Cases Brief Rep"},{"issue":"10","key":"321_CR81","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","volume":"136","author":"LA Acaba-Berrocal","year":"2018","unstructured":"Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL (2018) Birdshot-like chorioretinopathy associated with pembrolizumab treatment. JAMA Ophthalmol 136(10):1205\u20131207","journal-title":"JAMA Ophthalmol"},{"key":"321_CR82","doi-asserted-by":"crossref","unstructured":"A RA, Moll-Udina A, Martin R, Cilveti E, Subira O, Disfetano L, et al. Retinal Vasculitis Secondary to Durvalumab. Case Rep Ophthalmol. 2020;11(2):161\u20136.","DOI":"10.1159\/000507609"},{"issue":"4","key":"321_CR83","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R (2016) Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2(4):290\u2013293","journal-title":"JAAD Case Rep"},{"issue":"4","key":"321_CR84","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjd.14808","volume":"176","author":"H Montaudie","year":"2017","unstructured":"Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S (2017) Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176(4):1060\u20131063","journal-title":"Br J Dermatol"},{"key":"321_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100652","volume":"18","author":"C Ung","year":"2020","unstructured":"Ung C, Gragoudas E (2020) Checkpoint inhibitor-induced sarcoid choroidal granulomas. Am J Ophthalmol Case Rep 18:100652","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"14","key":"321_CR86","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000006278","volume":"91","author":"M Algaeed","year":"2018","unstructured":"Algaeed M, Mukharesh L, Heinzelmann M, Kaminski HJ (2018) Pearls & Oy-sters: pembrolizumab-induced myasthenia gravis. Neurology 91(14):e1365\u2013e1367","journal-title":"Neurology"},{"issue":"6","key":"321_CR87","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1002\/mus.25496","volume":"55","author":"I Alnahhas","year":"2017","unstructured":"Alnahhas I, Wong J (2017) A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve 55(6):E25\u2013E26","journal-title":"Muscle Nerve"},{"issue":"27","key":"321_CR88","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007350","volume":"96","author":"YH Chen","year":"2017","unstructured":"Chen YH, Liu FC, Hsu CH, Chian CF (2017) Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. Medicine (Baltimore) 96(27):e7350","journal-title":"Medicine (Baltimore)"},{"key":"321_CR89","doi-asserted-by":"publisher","first-page":"2539493","DOI":"10.1155\/2019\/2539493","volume":"2019","author":"M Fazel","year":"2019","unstructured":"Fazel M, Jedlowski PM (2019) Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports Immunol 2019:2539493","journal-title":"Case Reports Immunol"},{"issue":"3","key":"321_CR90","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","volume":"10","author":"Y Fukasawa","year":"2017","unstructured":"Fukasawa Y, Sasaki K, Natsume M, Nakashima M, Ota S, Watanabe K et al (2017) Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol 10(3):809\u2013812","journal-title":"Case Rep Oncol"},{"issue":"3","key":"321_CR91","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA (2017) Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27(3):266\u2013268","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"321_CR92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jemermed.2020.05.004","volume":"59","author":"AK Ho","year":"2020","unstructured":"Ho AK, Cooksley T (2020) Immune checkpoint inhibitor-mediated myasthenia gravis. J Emerg Med 59(4):561\u2013562","journal-title":"J Emerg Med"},{"key":"321_CR93","doi-asserted-by":"publisher","first-page":"5126717","DOI":"10.1155\/2020\/5126717","volume":"2020","author":"N Jeyakumar","year":"2020","unstructured":"Jeyakumar N, Etchegaray M, Henry J, Lelenwa L, Zhao B, Segura A et al (2020) The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol 2020:5126717","journal-title":"Case Reports Immunol"},{"issue":"33","key":"321_CR94","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR et al (2015) Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33(33):e122\u2013e124","journal-title":"J Clin Oncol"},{"issue":"1","key":"321_CR95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KH Lau","year":"2016","unstructured":"Lau KH, Kumar A, Yang IH, Nowak RJ (2016) Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54(1):157\u2013161","journal-title":"Muscle Nerve"},{"issue":"6","key":"321_CR96","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ceo.13499","volume":"47","author":"Q Liu","year":"2019","unstructured":"Liu Q, Ayyappan S, Broad A, Narita A (2019) Pembrolizumab-associated ocular myasthenia gravis. Clin Exp Ophthalmol 47(6):796\u2013798","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"321_CR97","volume":"12","author":"CJ Lorenzo","year":"2020","unstructured":"Lorenzo CJ, Fitzpatrick H, Campdesuner V, George J, Lattanzio N (2020) Pembrolizumab-Induced Ocular Myasthenic Crisis Cureus 12(7):e9192","journal-title":"Pembrolizumab-Induced Ocular Myasthenic Crisis Cureus"},{"issue":"1","key":"321_CR98","first-page":"119","volume":"78","author":"O Maeda","year":"2016","unstructured":"Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y (2016) Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 78(1):119\u2013122","journal-title":"Nagoya J Med Sci"},{"key":"321_CR99","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136","journal-title":"Eur J Cancer"},{"issue":"2","key":"321_CR100","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1078155216687389","volume":"24","author":"KL March","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE (2018) Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract 24(2):146\u2013149","journal-title":"J Oncol Pharm Pract"},{"key":"321_CR101","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fneur.2018.00150","volume":"9","author":"V Montes","year":"2018","unstructured":"Montes V, Sousa S, Pita F, Guerreiro R, Carmona C (2018) Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma. Front Neurol 9:150","journal-title":"Front Neurol"},{"issue":"11","key":"321_CR102","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2169\/internalmedicine.1956-18","volume":"58","author":"A Onda","year":"2019","unstructured":"Onda A, Miyagawa S, Takahashi N, Gochi M, Takagi M, Nishino I et al (2019) Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy. Intern Med 58(11):1635\u20131638","journal-title":"Intern Med"},{"key":"321_CR103","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jocn.2019.11.038","volume":"71","author":"TRA Ozarczuk","year":"2020","unstructured":"Ozarczuk TRA, Prentice DA, Kho LK, vanHeerden J (2020) Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy. J Clin Neurosci 71:271\u2013272","journal-title":"J Clin Neurosci"},{"issue":"1","key":"321_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2019-000028","volume":"2","author":"CS Phua","year":"2020","unstructured":"Phua CS, Murad A, Fraser C, Bray V, Cappelen-Smith C (2020) Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer. BMJ Neurol Open 2(1):e000028","journal-title":"BMJ Neurol Open"},{"issue":"3","key":"321_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25163","volume":"54","author":"P Polat","year":"2016","unstructured":"Polat P, Donofrio PD (2016) Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 54(3):507","journal-title":"Muscle Nerve"},{"issue":"3","key":"321_CR106","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25212","volume":"54","author":"G Sciacca","year":"2016","unstructured":"Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ, Zappia M (2016) Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 54(3):507\u2013509","journal-title":"Muscle Nerve"},{"issue":"1","key":"321_CR107","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M et al (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46(1):86\u201388","journal-title":"Jpn J Clin Oncol"},{"key":"321_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2020.101145","volume":"31","author":"M Takai","year":"2020","unstructured":"Takai M, Kato D, Iinuma K, Maekawa YM, Nakane K, Tsuchiya T et al (2020) Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report. Urol Case Rep 31:101145","journal-title":"Urol Case Rep"},{"issue":"11","key":"321_CR109","doi-asserted-by":"publisher","first-page":"omy094","DOI":"10.1093\/omcr\/omy094","volume":"2018","author":"T Tozuka","year":"2018","unstructured":"Tozuka T, Sugano T, Noro R, Takano N, Hisakane K, Takahashi S et al (2018) Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Reports 2018(11):omy094","journal-title":"Oxf Med Case Reports"},{"issue":"1","key":"321_CR110","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/0897190020970750","volume":"34","author":"AS Ziobro","year":"2021","unstructured":"Ziobro AS, LaPlante RL, DeMari SR, Clark LM, Kingsley DJ, Smith AJ (2021) Myasthenia gravis associated with programmed death-1 (PD-1) receptor inhibitor pembrolizumab: a 40-day case report. J Pharm Pract 34(1):166\u2013170","journal-title":"J Pharm Pract"},{"issue":"1","key":"321_CR111","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s42399-020-00706-1","volume":"3","author":"SAS Gutierrez","year":"2021","unstructured":"Gutierrez SAS, Damian LF (2021) New onset ocular myasthenia gravis after pembrolizumab therapy: a case report. SN Comprehensive Clinical Medicine 3(1):309\u2013311","journal-title":"SN Comprehensive Clinical Medicine"},{"issue":"7","key":"321_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.355","volume":"6","author":"M Hibino","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T (2018) Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep 6(7):e00355","journal-title":"Respirol Case Rep"},{"issue":"4","key":"321_CR113","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/j.cllc.2019.04.007","volume":"20","author":"MS Lara","year":"2019","unstructured":"Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW (2019) Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced nsclc and remote history of thymoma. Clin Lung Cancer 20(4):e489\u2013e491","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"321_CR114","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","volume":"8","author":"Q Xing","year":"2020","unstructured":"Xing Q, Zhang ZW, Lin QH, Shen LH, Wang PM, Zhang S et al (2020) Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. Ann Transl Med 8(5):250","journal-title":"Ann Transl Med"},{"issue":"6","key":"321_CR115","doi-asserted-by":"publisher","first-page":"e229149","DOI":"10.1136\/bcr-2018-229149","volume":"12","author":"A Dhenin","year":"2019","unstructured":"Dhenin A, Samartzi V, Lejeune S, Seront E (2019) Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Rep 12(6):e229149","journal-title":"BMJ Case Rep"},{"issue":"2","key":"321_CR116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","volume":"52","author":"AI Loochtan","year":"2015","unstructured":"Loochtan AI, Nickolich MS, Hobson-Webb LD (2015) Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52(2):307\u2013308","journal-title":"Muscle Nerve"},{"issue":"50","key":"321_CR117","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","volume":"96","author":"JH Chen","year":"2017","unstructured":"Chen JH, Lee KY, Hu CJ, Chung CC (2017) Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore) 96(50):e9262","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"321_CR118","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/1759-7714.13177","volume":"10","author":"JS Kim","year":"2019","unstructured":"Kim JS, Nam TS, Kim J, Kho BG, Park CK, Oh IJ et al (2019) Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: a case report. Thorac Cancer 10(10):2045\u20132049","journal-title":"Thorac Cancer"},{"issue":"4","key":"321_CR119","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1002\/mus.26021","volume":"57","author":"DE Earl","year":"2018","unstructured":"Earl DE, Loochtan AI, Bedlack RS (2018) Refractory myasthenia gravis exacerbation triggered By pembrolizumab. Muscle Nerve 57(4):E120\u2013E121","journal-title":"Muscle Nerve"},{"key":"321_CR120","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","volume":"83","author":"W Boisseau","year":"2017","unstructured":"Boisseau W, Touat M, Berzero G, Savatovsky J, Marabelle A, Touitou V et al (2017) Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer 83:28\u201331","journal-title":"Eur J Cancer"},{"issue":"11","key":"321_CR121","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","volume":"127","author":"JH Francis","year":"2020","unstructured":"Francis JH, Jaben K, Santomasso BD, Canestraro J, Abramson DH, Chapman PB et al (2020) Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology 127(11):1585\u20131589","journal-title":"Ophthalmology"},{"issue":"5","key":"321_CR122","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medicina54050082","volume":"54","author":"O Kartal","year":"2018","unstructured":"Kartal O, Atas E (2018) Bilateral optic neuritis secondary to Nivolumab therapy: a case report. Medicina (Kaunas) 54(5):82","journal-title":"Medicina (Kaunas)"},{"key":"321_CR123","doi-asserted-by":"crossref","unstructured":"Makri OE, Dimitrakopoulos FI, Tsapardoni F, Tsekouras I, Argyriou AA, Kalofonos H, et al. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. Int J Neurosci. 2020:1\u20136.","DOI":"10.1080\/00207454.2020.1831489"},{"issue":"2","key":"321_CR124","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000491075","volume":"9","author":"S Mori","year":"2018","unstructured":"Mori S, Kurimoto T, Ueda K, Enomoto H, Sakamoto M, Keshi Y et al (2018) Optic neuritis possibly induced by anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma. Case Rep Ophthalmol 9(2):348\u2013356","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"321_CR125","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1212\/NXI.0000000000000773","volume":"7","author":"M Nowosielski","year":"2020","unstructured":"Nowosielski M, Di Pauli F, Iglseder S, Wagner M, Hoellweger N, Nguyen VA et al (2020) Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 7(4):e773","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"321_CR126","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JOP.19.00438","volume":"16","author":"N Sengul Samanci","year":"2020","unstructured":"Sengul Samanci N, Ozan T, Celik E, Demirelli FH (2020) Optic neuritis related to atezolizumab treatment in a patient with metastatic non-small-cell lung cancer. JCO Oncol Pract 16(2):96\u201398","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"321_CR127","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","volume":"96","author":"A Vogrig","year":"2021","unstructured":"Vogrig A, Muniz-Castrillo S, Joubert B, Picard G, Rogemond V, Skowron F et al (2021) Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology 96(6):e866\u2013e875","journal-title":"Neurology"},{"key":"321_CR128","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-016-0170-9","volume":"4","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M et al (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66","journal-title":"J Immunother Cancer"},{"issue":"2","key":"321_CR129","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/WNO.0000000000000217","volume":"35","author":"OL Yeh","year":"2015","unstructured":"Yeh OL, Francis CE (2015) Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol 35(2):144\u2013147","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"321_CR130","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/01658107.2019.1566385","volume":"44","author":"KA Jaben","year":"2020","unstructured":"Jaben KA, Francis JH, Shoushtari AN, Abramson DH (2020) Isolated abducens nerve palsy following pembrolizumab. Neuroophthalmology 44(3):182\u2013185","journal-title":"Neuroophthalmology"},{"issue":"7","key":"321_CR131","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","volume":"265","author":"S Mancone","year":"2018","unstructured":"Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ et al (2018) Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 265(7):1636\u20131642","journal-title":"J Neurol"},{"issue":"3","key":"321_CR132","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","volume":"10","author":"Y Nakatani","year":"2018","unstructured":"Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K (2018) Lambert-eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10(3):346\u2013352","journal-title":"Case Rep Neurol"},{"issue":"3","key":"321_CR133","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1002\/mus.27141","volume":"63","author":"AJ Gill","year":"2021","unstructured":"Gill AJ, Gandhy S, Lancaster E (2021) Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63(3):E18\u2013E21","journal-title":"Muscle Nerve"},{"issue":"10","key":"321_CR134","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) Antibodies. JAMA Neurol 74(10):1216\u20131222","journal-title":"JAMA Neurol"},{"issue":"5","key":"321_CR135","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/01676830.2017.1423349","volume":"37","author":"R Alnabulsi","year":"2018","unstructured":"Alnabulsi R, Hussain A, DeAngelis D (2018) Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit 37(5):381\u2013384","journal-title":"Orbit"},{"issue":"3","key":"321_CR136","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/01658107.2017.1291686","volume":"41","author":"W Carrera","year":"2017","unstructured":"Carrera W, Baartman BJ, Kosmorsky G (2017) A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuroophthalmology 41(3):140\u2013143","journal-title":"Neuroophthalmology"},{"issue":"5","key":"321_CR137","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.nmd.2020.02.013","volume":"30","author":"M Garibaldi","year":"2020","unstructured":"Garibaldi M, Calabro F, Merlonghi G, Pugliese S, Ceccanti M, Cristiano L et al (2020) Immune checkpoint inhibitors (ICIs)-related ocular myositis. Neuromuscul Disord 30(5):420\u2013423","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"321_CR138","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/annonc\/mdw655","volume":"28","author":"CL Haddox","year":"2017","unstructured":"Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR et al (2017) Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28(3):673\u2013675","journal-title":"Ann Oncol"},{"issue":"3","key":"321_CR139","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/01676830.2018.1490439","volume":"38","author":"JB Hellman","year":"2019","unstructured":"Hellman JB, Traynis I, Lin LK (2019) Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia. Orbit 38(3):244\u2013247","journal-title":"Orbit"},{"issue":"1","key":"321_CR140","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","volume":"19","author":"H Kamo","year":"2019","unstructured":"Kamo H, Hatano T, Kanai K, Aoki N, Kamiyama D, Yokoyama K et al (2019) Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol 19(1):184","journal-title":"BMC Neurol"},{"issue":"6\u20137","key":"321_CR141","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annder.2013.02.029","volume":"140","author":"M Lecouflet","year":"2013","unstructured":"Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D et al (2013) Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 140(6\u20137):448\u2013451","journal-title":"Ann Dermatol Venereol"},{"key":"321_CR142","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","volume":"91","author":"F Nasr","year":"2018","unstructured":"Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J et al (2018) Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91:171\u2013173","journal-title":"Eur J Cancer"},{"issue":"7","key":"321_CR143","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","volume":"27","author":"H Vallet","year":"2016","unstructured":"Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V et al (2016) Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 27(7):1352\u20131353","journal-title":"Ann Oncol"},{"issue":"1","key":"321_CR144","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","volume":"30","author":"R Valenti-Azcarate","year":"2020","unstructured":"Valenti-Azcarate R, Esparragosa Vazquez I, Toledano Illan C, Idoate Gastearena MA, Gallego P-L (2020) Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation. Neuromuscul Disord 30(1):67\u201369","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"321_CR145","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","volume":"27","author":"G Borodic","year":"2011","unstructured":"Borodic G, Hinkle DM, Cia Y (2011) Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg 27(4):e87\u2013e88","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"321_CR146","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000485742","volume":"7","author":"P Campredon","year":"2018","unstructured":"Campredon P, Imbert P, Mouly C, Grunenwald S, Mazieres J, Caron P (2018) Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Eur Thyroid J 7(2):84\u201387","journal-title":"Eur Thyroid J"},{"issue":"6","key":"321_CR147","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/01676830.2014.949792","volume":"33","author":"E McElnea","year":"2014","unstructured":"McElnea E, Ni Mhealoid A, Moran S, Kelly R, Fulcher T (2014) Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 33(6):424\u2013427","journal-title":"Orbit"},{"issue":"2","key":"321_CR148","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-10-0833","volume":"164","author":"L Min","year":"2011","unstructured":"Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164(2):303\u2013307","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"321_CR149","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaapos.2018.01.006","volume":"22","author":"ESY Park","year":"2018","unstructured":"Park ESY, Rabinowits G, Hamnvik OR, Dagi LR (2018) A case of Graves\u2019 ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS 22(4):310\u2013312","journal-title":"J AAPOS"},{"issue":"12","key":"321_CR150","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JOP.18.00442","volume":"14","author":"L Rhea","year":"2018","unstructured":"Rhea L, Yoon JW, Jang S (2018) Rapid development of graves\u2019 ophthalmopathy after treatment with ipilimumab and recurrence with pembrolizumab in a patient with previously treated graves\u2019 disease. J Oncol Pract 14(12):747\u2013749","journal-title":"J Oncol Pract"},{"issue":"7","key":"321_CR151","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40618-018-0906-0","volume":"41","author":"E Sabini","year":"2018","unstructured":"Sabini E, Sframeli A, Marino M (2018) A case of drug-induced Graves\u2019 Orbitopathy after combination therapy with Tremelimumab and Durvalumab. J Endocrinol Invest 41(7):877\u2013878","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"321_CR152","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","volume":"35","author":"O Sagiv","year":"2019","unstructured":"Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M et al (2019) Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg 35(1):50\u201352","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"321_CR153","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/01658107.2017.1368090","volume":"42","author":"B Hassanzadeh","year":"2018","unstructured":"Hassanzadeh B, DeSanto J, Kattah JC (2018) Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management. Neuroophthalmology 42(3):176\u2013181","journal-title":"Neuroophthalmology"},{"issue":"3","key":"321_CR154","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/IOP.0000000000000081","volume":"31","author":"AD Henderson","year":"2015","unstructured":"Henderson AD, Thomas DA (2015) A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthalmic Plast Reconstr Surg 31(3):e68-70","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"321_CR155","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10637-018-0659-9","volume":"37","author":"C Nardin","year":"2019","unstructured":"Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS et al (2019) Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. Invest New Drugs 37(2):375\u2013377","journal-title":"Invest New Drugs"},{"issue":"3S Suppl 1","key":"321_CR156","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1097\/IOP.0000000000000509","volume":"33","author":"CA Sheldon","year":"2017","unstructured":"Sheldon CA, Kharlip J, Tamhankar MA (2017) Inflammatory orbitopathy associated with ipilimumab. Ophthalmic Plast Reconstr Surg 33(3S Suppl 1):S155\u2013S8","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"321_CR157","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/IOP.0b013e3182895795","volume":"29","author":"MA Sohrab","year":"2013","unstructured":"Sohrab MA, Desai RU, Chambers CB, Lissner GS (2013) Re: \u201cDrug-induced Graves disease from CTLA-4 receptor suppression.\u201d Ophthalmic Plast Reconstr Surg 29(3):239\u2013240","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"7","key":"321_CR158","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/CJI.0000000000000224","volume":"41","author":"E Ileana Dumbrava","year":"2018","unstructured":"Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM (2018) Autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy. J Immunother 41(7):336\u2013339","journal-title":"J Immunother"},{"issue":"3","key":"321_CR159","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","volume":"35","author":"AT Nguyen","year":"2016","unstructured":"Nguyen AT, Elia M, Materin MA, Sznol M, Chow J (2016) Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation. Cornea 35(3):399\u2013401","journal-title":"Cornea"},{"issue":"33","key":"321_CR160","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","volume":"30","author":"C Voskens","year":"2012","unstructured":"Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356\u2013e357","journal-title":"J Clin Oncol"},{"issue":"9","key":"321_CR161","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24(9):1259\u20131269","journal-title":"Oncologist"},{"issue":"12","key":"321_CR162","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1093\/annonc\/mdx531","volume":"28","author":"D Teyssonneau","year":"2017","unstructured":"Teyssonneau D, Cousin S, Italiano A (2017) Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Ann Oncol 28(12):3108","journal-title":"Ann Oncol"},{"issue":"1","key":"321_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1):e53745","journal-title":"PLoS ONE"},{"issue":"1","key":"321_CR164","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","volume":"6","author":"A Horisberger","year":"2018","unstructured":"Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G et al (2018) A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 6(1):156","journal-title":"J Immunother Cancer"},{"issue":"6","key":"321_CR165","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/ceo.13139","volume":"46","author":"CC Hsiao","year":"2018","unstructured":"Hsiao CC, Yao M, Liu JH, Chen WL (2018) Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation. Clin Exp Ophthalmol 46(6):698\u2013700","journal-title":"Clin Exp Ophthalmol"},{"key":"321_CR166","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajoc.2019.01.013","volume":"14","author":"JS Parker","year":"2019","unstructured":"Parker JS, Feagin W, Wang C, Heersink M, Parker JS (2019) Corneal ulceration associated with Nivolumab use. Am J Ophthalmol Case Rep 14:26\u201327","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"321_CR167","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1078155219877219","volume":"26","author":"S Thomas","year":"2020","unstructured":"Thomas S, Bae C, Joy-Ann T, Traverse W (2020) Behcet\u2019s-like syndrome following pembrolizumab: an immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. J Oncol Pharm Pract 26(4):995\u2013999","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"321_CR168","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/ICO.0000000000002490","volume":"40","author":"A Ramaekers","year":"2021","unstructured":"Ramaekers A, Aspeslagh S, De Brucker N, Van Mierlo C, Ten Tusscher M, Schauwvlieghe PP et al (2021) Bilateral corneal perforation in a patient under anti-PD1 therapy. Cornea 40(2):245\u2013247","journal-title":"Cornea"},{"key":"321_CR169","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","volume":"102","author":"S Le Fournis","year":"2016","unstructured":"Le Fournis S, Gohier P, Urban T, Jeanfaivre T, Hureaux J (2016) Corneal graft rejection in a patient treated with nivolumab for primary lung cancer. Lung Cancer 102:28\u201329","journal-title":"Lung Cancer"},{"issue":"11","key":"321_CR170","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/ICO.0000000000002372","volume":"39","author":"E Vanhonsebrouck","year":"2020","unstructured":"Vanhonsebrouck E, Van De Walle M, Lybaert W, Kruse V, Roels D (2020) Bilateral corneal graft rejection associated with pembrolizumab treatment. Cornea 39(11):1436\u20131438","journal-title":"Cornea"},{"issue":"2","key":"321_CR171","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000353408","volume":"227","author":"A Audemard","year":"2013","unstructured":"Audemard A, de Raucourt S, Miocque S, Comoz F, Giraud JM, Dreno B et al (2013) Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology 227(2):146\u2013149","journal-title":"Dermatology"},{"issue":"5","key":"321_CR172","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/ICB.0000000000000882","volume":"15","author":"KF Elwood","year":"2021","unstructured":"Elwood KF, Pulido JS, Ghafoori SD, Harper CA, Wong RW (2021) Choroidal neovascularization and chorioretinal atrophy in a patient with melanoma-associated retinopathy after ipilimumab\/nivolumab combination therapy. Retin Cases Brief Rep 15(5):514\u2013518","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"321_CR173","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10633-020-09795-8","volume":"142","author":"L Poujade","year":"2021","unstructured":"Poujade L, Samaran Q, Mura F, Guillot B, Meunier I, Du-Thanh A (2021) Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone. Doc Ophthalmol 142(2):257\u2013263","journal-title":"Doc Ophthalmol"},{"issue":"10","key":"321_CR174","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","volume":"134","author":"P Roberts","year":"2016","unstructured":"Roberts P, Fishman GA, Joshi K, Jampol LM (2016) Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol 134(10):1184\u20131188","journal-title":"JAMA Ophthalmol"},{"key":"321_CR175","unstructured":"Kemels D, Ten Berge JC, Jacob J, Schauwvlieghe PP. The role of Checkpoint Inhibitors in Paraneoplastic Acute Exudative Polymorphous Vitelliform Maculopathy: report of two cases. Retin Cases Brief Rep. 2020."},{"issue":"1","key":"321_CR176","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12886-021-02011-4","volume":"21","author":"I Lambert","year":"2021","unstructured":"Lambert I, Fasolino G, Awada G, Kuijpers R, Ten Tusscher M, Neyns B (2021) Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report. BMC Ophthalmol 21(1):250","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"321_CR177","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","volume":"133","author":"D Mantopoulos","year":"2015","unstructured":"Mantopoulos D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133(8):965\u2013967","journal-title":"JAMA Ophthalmol"},{"key":"321_CR178","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/IMCRJ.S225173","volume":"12","author":"T Miyakubo","year":"2019","unstructured":"Miyakubo T, Mukai R, Nakamura K, Matsumoto H, Akiyama H (2019) A case of ipilimumab-induced unusual serous retinal detachment in bilateral eyes. Int Med Case Rep J 12:355\u2013361","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"321_CR179","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12886-020-01495-w","volume":"20","author":"R Miyamoto","year":"2020","unstructured":"Miyamoto R, Nakashizuka H, Tanaka K, Wakatsuki Y, Onoe H, Mori R et al (2020) Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report. BMC Ophthalmol 20(1):221","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"321_CR180","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ICB.0000000000000604","volume":"13","author":"HS Sandhu","year":"2019","unstructured":"Sandhu HS, Kolomeyer AM, Lau MK, Shields CL, Schuchter LM, Nichols CW et al (2019) Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep 13(2):103\u2013107","journal-title":"Retin Cases Brief Rep"},{"issue":"2","key":"321_CR181","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/ICB.0000000000000675","volume":"14","author":"M Reddy","year":"2020","unstructured":"Reddy M, Chen JJ, Kalevar A, Terribilini R, Agarwal A (2020) Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer. Retin Cases Brief Rep 14(2):120\u2013126","journal-title":"Retin Cases Brief Rep"},{"key":"321_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100799","volume":"19","author":"J Canestraro","year":"2020","unstructured":"Canestraro J, Jaben KA, Wolchok JD, Abramson DH, Francis JH (2020) Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. Am J Ophthalmol Case Rep 19:100799","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"321_CR183","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1111\/aos.14237","volume":"98","author":"J Krohn","year":"2020","unstructured":"Krohn J, Hanken G, Herlofsen O (2020) Choroidal naevus regression associated with PD-1 inhibitor monotherapy for metastatic cutaneous malignant melanoma. Acta Ophthalmol 98(2):e262\u2013e264","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"321_CR184","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaophthalmol.2019.0970","volume":"137","author":"R Sophie","year":"2019","unstructured":"Sophie R, Moses GM, Hwang ES, Kim JE (2019) Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with nivolumab. JAMA Ophthalmol 137(7):851\u2013853","journal-title":"JAMA Ophthalmol"},{"key":"321_CR185","doi-asserted-by":"crossref","unstructured":"Ipilimumab: Bilateral choroidal neovascularisation in an elderly patient: case report. Reactions weekly. 2013;1469(1):27-.","DOI":"10.1007\/s40278-013-5836-1"},{"issue":"4","key":"321_CR186","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.oret.2019.11.006","volume":"4","author":"P Ramtohul","year":"2020","unstructured":"Ramtohul P, Freund KB (2020) Clinical and morphological characteristics of anti-programmed death ligand 1-associated retinopathy: expanding the spectrum of acute macular neuroretinopathy. Ophthalmol Retina 4(4):446\u2013450","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"321_CR187","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","volume":"31","author":"T Fang","year":"2019","unstructured":"Fang T, Maberley DA, Etminan M (2019) Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol 31(3):319\u2013322","journal-title":"J Curr Ophthalmol"},{"issue":"4","key":"321_CR188","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.soncn.2017.08.003","volume":"33","author":"ME Davis","year":"2017","unstructured":"Davis ME, Francis JH (2017) Cancer therapy with checkpoint inhibitors: establishing a role for ophthalmology. Semin Oncol Nurs 33(4):415\u2013424","journal-title":"Semin Oncol Nurs"},{"key":"321_CR189","doi-asserted-by":"crossref","unstructured":"Sarkar P, Mehtani A, Gandhi HC, Bhalla JS, Tapariya S. Paraneoplastic ocular syndrome: a pandora's box of underlying malignancies. Eye (Lond). 2021.","DOI":"10.1038\/s41433-021-01676-x"},{"issue":"4","key":"321_CR190","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Muniz-Castrillo S, Antoine JG, Desestret V, Dubey D et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8(4):e1014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"321_CR191","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535\u2013548","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"321_CR192","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00417-003-0787-5","volume":"241","author":"S Aisenbrey","year":"2003","unstructured":"Aisenbrey S, Luke C, Ayertey HD, Grisanti S, Perniok A, Brunner R (2003) Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefes Arch Clin Exp Ophthalmol 241(12):996\u2013999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"321_CR193","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1172\/JCI42440","volume":"120","author":"RR Caspi","year":"2010","unstructured":"Caspi RR (2010) A look at autoimmunity and inflammation in the eye. J Clin Invest 120(9):3073\u20133083","journal-title":"J Clin Invest"},{"issue":"1","key":"321_CR194","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-016-0429-8","volume":"11","author":"E Minos","year":"2016","unstructured":"Minos E, Barry RJ, Southworth S, Folkard A, Murray PI, Duker JS et al (2016) Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis 11(1):61","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"321_CR195","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134","journal-title":"J Immunother Cancer"},{"key":"321_CR196","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.578091","volume":"11","author":"Z Huang","year":"2020","unstructured":"Huang Z, Su W, Lu T, Wang Y, Dong Y, Qin Y et al (2020) First-Line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress. Front Pharmacol 11:578091","journal-title":"Front Pharmacol"},{"issue":"11","key":"321_CR197","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2169\/internalmedicine.54.3363","volume":"54","author":"K Niimi","year":"2015","unstructured":"Niimi K, Nagata E, Murata N, Sato M, Tanaka J, Horio Y et al (2015) Lung cancer associated with seronegative myasthenia gravis. Intern Med 54(11):1381\u20131384","journal-title":"Intern Med"},{"key":"321_CR198","unstructured":"Tirthani E, Said MS, Smith RG, Jadhav N, Shanina E. Paraneoplastic Encephalomyelitis. StatPearls. Treasure Island (FL)2022."},{"issue":"4","key":"321_CR199","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","volume":"17","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M et al (2017) Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther 17(4):387\u2013394","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"321_CR200","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10633-020-09772-1","volume":"141","author":"MS Kim","year":"2020","unstructured":"Kim MS, Hong HK, Ko YJ, Park KH, Ueno S, Okado S et al (2020) A case of melanoma-associated retinopathy with autoantibodies against TRPM1. Doc Ophthalmol 141(3):313\u2013318","journal-title":"Doc Ophthalmol"},{"issue":"9","key":"321_CR201","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00262-021-02875-x","volume":"70","author":"K Khaddour","year":"2021","unstructured":"Khaddour K, Khanna S, Ansstas M, Jakhar I, Dahiya S, Council L et al (2021) Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. Cancer Immunol Immunother 70(9):2497\u20132502","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"321_CR202","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00041327-200109000-00004","volume":"21","author":"JL Keltner","year":"2001","unstructured":"Keltner JL, Thirkill CE, Yip PT (2001) Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 21(3):173\u2013187","journal-title":"J Neuroophthalmol"},{"key":"321_CR203","doi-asserted-by":"crossref","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221\u201336; quiz 37\u20138.","DOI":"10.1016\/j.jaad.2014.07.033"},{"issue":"5","key":"321_CR204","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.survophthal.2016.03.003","volume":"61","author":"KV Bhavsar","year":"2016","unstructured":"Bhavsar KV, Lin S, Rahimy E, Joseph A, Freund KB, Sarraf D et al (2016) Acute macular neuroretinopathy: a comprehensive review of the literature. Surv Ophthalmol 61(5):538\u2013565","journal-title":"Surv Ophthalmol"},{"key":"321_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101232","volume":"24","author":"JA David","year":"2021","unstructured":"David JA, Fivgas GD (2021) Acute macular neuroretinopathy associated with COVID-19 infection. Am J Ophthalmol Case Rep 24:101232","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"321_CR206","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659\u2013668","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"321_CR207","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"1","key":"321_CR208","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","volume":"7","author":"G Manson","year":"2019","unstructured":"Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S et al (2019) Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer 7(1):337","journal-title":"J Immunother Cancer"},{"issue":"6","key":"321_CR209","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1124\/mol.113.086470","volume":"83","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Asavapanumas N, Verkman AS (2013) Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol 83(6):1268\u20131275","journal-title":"Mol Pharmacol"},{"issue":"1","key":"321_CR210","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Ratelade J, Zhang H, Verkman AS (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73(1):77\u201385","journal-title":"Ann Neurol"},{"issue":"6","key":"321_CR211","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B et al (2021) Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology 96(6):e853\u2013e865","journal-title":"Neurology"},{"issue":"23","key":"321_CR212","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23):e2661\u2013e2673","journal-title":"Neurology"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-022-00321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-022-00321-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-022-00321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T07:30:22Z","timestamp":1701934222000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-022-00321-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":212,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1186\/s12348-022-00321-2","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"9 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the guidelines of the Belgian legislation and the Research Ethics Committee of the University Hospitals of Leuven.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicting relationship exists for any author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}